Related references
Note: Only part of the references are listed.The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers
A. J. Atherly et al.
BRITISH JOURNAL OF CANCER (2012)
Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement
Hye Ryun Kim et al.
CANCER (2012)
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer
Robert C. Doebele et al.
CLINICAL CANCER RESEARCH (2012)
Inhibitors of the anaplastic lymphoma kinase
Luca Mologni
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: A comprehensive study of Caucasian non-smokers
Pierre-Alexandre Just et al.
LUNG CANCER (2012)
Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene
Takayuki Fukui et al.
LUNG CANCER (2012)
KLC1-ALK: A Novel Fusion in Lung Cancer Identified Using a Formalin-Fixed Paraffin-Embedded Tissue Only
Yuki Togashi et al.
PLOS ONE (2012)
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Ryohei Katayama et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
ALK inhibitors, a pharmaceutical perspective
Elena Ardini et al.
FRONTIERS IN ONCOLOGY (2012)
Comprehensive Histologic Analysis of ALK-Rearranged Lung Carcinomas
Akihiko Yoshida et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2011)
Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice
L. V. Sequist et al.
ANNALS OF ONCOLOGY (2011)
A Novel KIF5B-ALK Variant in Nonsmall Cell Lung Cancer
Daisy Wing-Sze Wong et al.
CANCER (2011)
A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
Takaaki Sasaki et al.
CANCER RESEARCH (2011)
MET Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib
Jochen K. Lennerz et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
J. Jean Cui et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Anaplastic lymphoma kinase in human cancer
Antonella Barreca et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2011)
Screening of Anaplastic Lymphoma Kinase Rearrangement by Immunohistochemistry in Non-small Cell Lung Cancer Correlation with Fluorescence In Situ Hybridization
Jin Ho Paik et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung Cancer
Marta Salido et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Lung Adenocarcinoma with Concurrent Exon 19 EGFR Mutation and ALK Rearrangement Responding to Erlotinib
Sanjay Popat et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma Suggestion for an Effective Screening Strategy for These Tumors
Youngil Koh et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Correlation of IHC and FISH for ALK Gene Rearrangement in Non-small Cell Lung Carcinoma IHC Score Algorithm for FISH
Eunhee S. Yi et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Anaplastic Lymphoma Kinase Translocation A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer
Jeong-Ok Lee et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Detection of ALK Gene Rearrangement in Non-small Cell Lung Cancer A Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization with Correlation of ALK Protein Expression
Hyojin Kim et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
EGFR and EML4-ALK gene mutations in NSCLC: A case report of erlotinilb-resistant patient with both concomitant mutations
M. Tiseo et al.
LUNG CANCER (2011)
Crizotinib in Anaplastic Large-Cell Lymphoma
Carlo Gambacorti-Passerini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels
Floor A. M. Duijkers et al.
CELLULAR ONCOLOGY (2011)
Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond
Sai-Hong Ignatius Ou
DRUG DESIGN DEVELOPMENT AND THERAPY (2011)
A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry
Mari Mino-Kenudson et al.
CLINICAL CANCER RESEARCH (2010)
Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment
D. Ross Camidge et al.
CLINICAL CANCER RESEARCH (2010)
The biology and treatment of EML4-ALK non-small cell lung cancer
Takaaki Sasaki et al.
EUROPEAN JOURNAL OF CANCER (2010)
Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases
Yihua Sun et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma
Ryu Jokoji et al.
JOURNAL OF CLINICAL PATHOLOGY (2010)
Treatment of Lung Cancer with an ALK Inhibitor After EML4-ALK Fusion Gene Detection Using Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration
Takahiro Nakajima et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
Xuchao Zhang et al.
MOLECULAR CANCER (2010)
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Cory M. Johannessen et al.
NATURE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Targeted therapy in non-small-cell lung cancer-is it becoming a reality?
Filip Janku et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor
James E. Butrynski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Young Lim Choi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Molecular pathogenesis of peripheral neuroblastic tumors
I. Janoueix-Lerosey et al.
ONCOGENE (2010)
Chromosomal and genomic changes in lung cancer
Marileila Varella-Garcia
CELL ADHESION & MIGRATION (2010)
EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung Tissues
Maria Paola Martelli et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Anaplastic lymphoma kinase: signalling in development and disease
Ruth H. Palmer et al.
BIOCHEMICAL JOURNAL (2009)
The EML4-ALK Fusion Gene Is Involved in Various Histologic Types of Lung Cancers From Nonsmokers With Wild-type EGFR and KRAS
Daisy Wing-Sze Wong et al.
CANCER (2009)
KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer
Kengo Takeuchi et al.
CLINICAL CANCER RESEARCH (2009)
Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population
Scott J. Rodig et al.
CLINICAL CANCER RESEARCH (2009)
Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas
Jennifer M. Boland et al.
HUMAN PATHOLOGY (2009)
Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK
Alice T. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
EML4-ALK: Honing In on a New Target in Non-Small-Cell Lung Cancer
Leora Horn et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
ALK Gene Rearrangements A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer
Benjamin Solomon et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset
Kentaro Inamura et al.
MODERN PATHOLOGY (2009)
GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers
Peter Sabbatini et al.
MOLECULAR CANCER THERAPEUTICS (2009)
High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours
Helena Caren et al.
BIOCHEMICAL JOURNAL (2008)
Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts
Kengo Takeuchi et al.
CLINICAL CANCER RESEARCH (2008)
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer
Jussi P. Koivunen et al.
CLINICAL CANCER RESEARCH (2008)
EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers
Kentaro Inamura et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas
Kazuya Shinmura et al.
LUNG CANCER (2008)
A mouse model for EML4-ALK-positive lung cancer
Manabu Soda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Cai-Hong Yun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The anaplastic lymphoma kinase in the pathogenesis of cancer
Roberto Chiarle et al.
NATURE REVIEWS CANCER (2008)
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
Klarisa Rikova et al.
CELL (2007)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms
Helen Y. Zou et al.
CANCER RESEARCH (2007)
Echinoderm microtubule-associated protein like protein 4, a member of the echinoderm microtubule-associated protein family, stabilizes microtubules
S. H. Houtman et al.
NEUROSCIENCE (2007)
Update in the treatment of brain Metastases from lung cancer
Amanda L. Schwer et al.
CLINICAL LUNG CANCER (2006)
Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer
Y Tomizawa et al.
CLINICAL CANCER RESEARCH (2005)
Biological role of anaplastic lymphoma kinase in neuroblastoma
Y Osajima-Hakomori et al.
AMERICAN JOURNAL OF PATHOLOGY (2005)
EGF activates an inducible survival response via the RAS-> Erk-1/2 pathway to counteract interferon-α-mediated apoptosis in epidermoid cancer cells
M Caraglia et al.
CELL DEATH AND DIFFERENTIATION (2003)
Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas -: Identification of a new TFG-ALKXL chimeric gene with transforming activity
L Hernández et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway
B Souttou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Share Paper
